ICUI

Business Context and Reporting Period

Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2008
Business Overview: ICU Medical is a developer, manufacturer, and seller of proprietary disposable medical connection systems for vascular therapy, custom I.V. systems, and critical care medical devices. The company's primary product is the CLAVE needleless I.V. connection system. Operations are headquartered in San Clemente, California, with significant manufacturing facilities in Salt Lake City, Utah, and Ensenada, Mexico.

Key Financial Metrics

Note: The company reported no long-term debt or current maturities of long-term debt on the balance sheet.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 9% to $204.7 million, driven by growth in CLAVE products (+11%) and custom products (+20%).
• Product Mix Shift: CLAVE products accounted for 39% of revenue (up from 38%), while custom products rose to 34% (up from 31%). Conversely, critical care product sales declined 16% to $36.5 million due to lower unit sales and pricing pressures under the Manufacturing, Commercialization and Development Agreement (MCDA) with Hospira.
• Customer Concentration: Sales to Hospira remained the dominant revenue source, accounting for 69% of total revenue ($132.6 million), a slight decrease from 73% in 2007.
• Expense Management: Selling, General, and Administrative (SG&A) expenses increased to $53.6 million (26% of revenue) from $45.5 million (24% of revenue), primarily due to higher compensation and marketing costs. Research and Development (R&D) expenses decreased significantly to $4.8 million (2% of revenue) from $8.1 million (4% of revenue) due to a refocus on core projects.
• Other Income: Other income decreased to $4.7 million from $8.7 million, largely due to lower interest rates and the absence of a one-time $8.0 million litigation settlement received in 2007.

Guidance, Outlook, and Risks

Management Commentary and Outlook

• 2009 Guidance: Management estimates gross margins will approximate 43-44%. SG&A is expected to be 26-27% of revenue, and R&D is expected to be 1-2% of revenue. The effective tax rate is projected at approximately 36%.
• Strategic Focus: The company plans to continue expanding its custom I.V. systems and oncology product lines to reduce dependence on the CLAVE and critical care segments. International sales are expected to grow modestly.
• Capital Allocation: Capital expenditures for 2009 are estimated at $15.0 million. The company has a $40.0 million stock repurchase program authorized in July 2008; $5.9 million was utilized in Q4 2008.

Risks and Contingencies

• Hospira Dependence: The loss of Hospira as a customer or a deterioration in their market position would have a significant adverse effect on the business.
• Patent Litigation: The company is involved in ongoing patent litigation. A $5.0 million judgment against the company in the ICU Medical v. Alaris case was recorded in 2007 and remains unpaid pending appeal. Additionally, the Medegen v. ICU Medical case was remanded to the District Court after a Federal Circuit reversal in November 2008.
• Market Risks: The company faces risks related to the liquidity of auction rate securities (though mitigated by agreements with Morgan Stanley and UBS), foreign currency fluctuations (Euro exposure), and raw material costs (resins).
• Acquisition: In December 2008, the company signed an agreement to acquire a German oncology manufacturing and distribution company for approximately €4.2 million, contingent on court approval.

Investor Verification Checklist

• Hospira Relationship Stability: Verify the status of the MCDA and distribution agreements with Hospira, which represent nearly 70% of revenue.
• Patent Litigation Status: Monitor the outcome of the appeal in ICU Medical v. Alaris (potential $5M liability) and the remanded Medegen case.
• Custom Product Growth: Assess whether the growth in custom I.V. and oncology products is sufficient to offset the structural decline in the critical care segment.
• Auction Rate Securities: Review the progress of the settlement agreements with Morgan Stanley and UBS regarding the company's illiquid auction rate securities.
• German Acquisition: Confirm the closing of the German oncology acquisition and its integration timeline.